Literature DB >> 17371250

Chemically targeting the PI3K family.

Z A Knight1, K M Shokat.   

Abstract

PI3K (phosphoinositide 3-kinase) is a key regulator of cell growth, metabolism and survival. The frequent activation of the PI3K pathway in cancer has stimulated widespread interest in identifying potent and selective inhibitors of PI3K isoforms. The present paper highlights recent progress in identifying such molecules and the challenges that remain for efforts to pharmacologically target the PI3K family.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371250     DOI: 10.1042/BST0350245

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  44 in total

1.  Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy.

Authors:  Thomas Farkas; Mads Daugaard; Marja Jäättelä
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

Review 2.  Autophagy inhibitors.

Authors:  Benoit Pasquier
Journal:  Cell Mol Life Sci       Date:  2015-12-11       Impact factor: 9.261

Review 3.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

Review 5.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

6.  Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues.

Authors:  Yingjie Sun; Shengqing Yu; Na Ding; Chunchun Meng; Songshu Meng; Shilei Zhang; Yuan Zhan; Xusheng Qiu; Lei Tan; Hongjun Chen; Cuiping Song; Chan Ding
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

7.  Single-cell analysis of phosphoinositide 3-kinase and phosphatase and tensin homolog activation.

Authors:  Dechen Jiang; Christopher Eldridge Sims; Nancy Lynn Allbritton
Journal:  Faraday Discuss       Date:  2011       Impact factor: 4.008

Review 8.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesis.

Authors:  Shannon McNulty; William Bornmann; Jill Schriewer; Chas Werner; Scott K Smith; Victoria A Olson; Inger K Damon; R Mark Buller; John Heuser; Daniel Kalman
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

10.  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.

Authors:  Beth Apsel; Jimmy A Blair; Beatriz Gonzalez; Tamim M Nazif; Morri E Feldman; Brian Aizenstein; Randy Hoffman; Roger L Williams; Kevan M Shokat; Zachary A Knight
Journal:  Nat Chem Biol       Date:  2008-10-12       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.